Assessing Stoke Therapeutics (STOK) Valuation After Strong 1 Year Shareholder Returns
Stoke Therapeutics (STOK), a clinical-stage biotech focusing on severe genetic diseases, has seen significant 1-year shareholder returns, prompting a valuation assessment. Despite recent short-term share price declines, the company is considered modestly undervalued at $32.74 against a narrative fair value of $34.25, according to analyst consensus. This valuation is based on expectations of future earnings growth and profit margins, though there is a range in analyst price targets, and the valuation could be sensitive to clinical trial outcomes like Phase 3 data for zorevunersen.
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK)
Barry Ticho, Chief Medical Officer at Stoke Therapeutics Inc (STOK), sold 1,838 shares on April 1, 2026, reducing his holdings to 38,864 shares. Over the past year, Ticho has sold 88,961 shares with no purchases, and the company has seen 37 insider sells and no buys. Stoke Therapeutics, trading at $32.66 with a market cap of $1.936 billion, is considered a "Possible Value Trap" based on its GF Value of $58.70.
Stoke Therapeutics (STOK) CMO sells 1,838 shares in planned open-market trade
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 1,838 shares of common stock at an average price of $32.66 per share in a pre-arranged open-market transaction. This sale, conducted under a Rule 10b5-1 trading plan, leaves him with 38,864 shares directly held. The transaction was disclosed via a Form 4 filing and is considered neutral in impact with negative sentiment by Rhea-AI.
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79
This article reports that Stoke Therapeutics (STOK) has received a price target increase of 16.51%, raising it to $28.79. The news indicates a positive analyst outlook for the company's stock.
Insider sells shares under 10b5-1 — STOK (NASDAQ: STOK) discloses trades
A recent SEC Form 144 filing from Stoke Therapeutics (NASDAQ: STOK) reveals routine Rule 10b5-1 sales by insider Baruch S. Ticho. These sales, executed in March 2026, involved common stock on three separate dates with specified share counts and gross proceeds. The filing also notes Restricted Stock Units dated December 1, 2025, but does not disclose any material corporate actions or unexpected events.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
Stoke Therapeutics (NASDAQ:STOK) has received an average "Moderate Buy" rating from twelve analysts, with a consensus 12-month target price of $41.83. The biopharmaceutical company, focused on genetic medicines for rare disorders, currently trades around $32.56. Despite ongoing unprofitability and recent insider stock sales, institutional investors maintain significant holdings.
STOK Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Stoke Therapeutics Inc (STOK), detailing its revenue breakdown, profitability margins, and a comparison with competitors MLYS and TYRA. It highlights STOK's gross margin of 100.00% but also notes negative operating and net margins, along with a negative Return on Equity (ROE). The company has a market capitalization of $1.89B.
Stoke Therapeutics Hits Day High with 7.98% Surge in Strong Intraday Performance
Stoke Therapeutics, a small-cap company in the Pharmaceuticals & Biotechnology sector, experienced a 7.98% surge to an intraday high of USD 38.69. The company has shown significant stock performance over various time frames, including a 378.28% return in the last year, outperforming the S&P 500, and reported a substantial 151.4% increase in net sales. Despite this, it faces challenges such as a low return on equity and a decrease in promoter stake.
Stoke Therapeutics (STOK) Valuation After Strong 2025 Results And Progress In STK-002 And Zorevunersen
Stoke Therapeutics (STOK) reported strong 2025 results with US$184.42 million in sales and pipeline progress for STK-002 and zorevunersen, leading to a 355.62% shareholder return over the past year. Despite a recent 9.78% decline in share price, Simply Wall St's narrative suggests a fair value of $34.25, implying it is 4.1% undervalued, although its P/S ratio of 10.5x is above the US Biotech average. The valuation hinges on successful Phase 3 trials for zorevunersen and favorable regulatory conditions.
Stoke Therapeutics, Inc. Files 8-K Announcing Change in Certifying Accountant – March 2026
Stoke Therapeutics, Inc. (NASDAQ: STOK) has filed an 8-K announcing a change in its independent registered public accounting firm. The company dismissed KPMG LLP and appointed Ernst & Young LLP (EY), effective March 23, 2026. This transition was not due to any disagreements or financial concerns, and KPMG had issued clean audit opinions for 2024 and 2025.
Stoke Therapeutics (STOK) price target increased by 12.11% to 43.96
The article reports that the price target for Stoke Therapeutics (STOK) has been increased by 12.11% to $43.96. The content provided is minimal, only stating the increased price target.
Stoke Therapeutics (NASDAQ: STOK) replaces KPMG with EY as auditor
Stoke Therapeutics has announced the replacement of its independent auditor, dismissing KPMG LLP and appointing Ernst & Young LLP (EY) for the fiscal year ending December 31, 2026. The company confirmed that KPMG's previous audit reports for 2024 and 2025 contained no adverse opinions or disagreements, and similarly, no consultations were held with EY regarding accounting matters prior to their appointment. This change was formally disclosed in an 8-K filing with the SEC.
Vanguard reports zero Stoke Therapeutics holdings (STOK)
The Vanguard Group filed an amended Schedule 13G/A, reporting zero shares of Stoke Therapeutics Inc. (STOK) common stock. This change is attributed to an internal realignment effective January 12, 2026, which disaggregated certain subsidiaries' holdings according to SEC Release No. 34-39538, rather than a sale of shares. The filing indicates that these subsidiaries will now report their beneficial ownership separately.
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) experienced an unusually high trading volume, with shares increasing 240% from the previous session. Despite notable insider selling, analysts maintain a "Moderate Buy" consensus with an average price target of $41.83, some as high as $60. The company, focused on genetic medicines for rare disorders, also saw significant institutional investment in the last quarter.
Stoke Therapeutics Insider Sold Shares Worth $313,038, According to a Recent SEC Filing
An insider at Stoke Therapeutics sold shares valued at $313,038, as indicated by a recent SEC filing. The article highlights this transaction and lists other recent news concerning Stoke Therapeutics, Inc., including earlier insider stock sales and analyst ratings. The company focuses on developing RNA-based medicines for severe genetic diseases.
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock
Jonathan Allan, General Counsel of Stoke Therapeutics, sold 9,293 shares of STOK stock for $313,038 under a 10b5-1 trading plan. This sale occurred on March 20, 2026, with the stock trading near its 52-week high after a 303% return over the past year. The company has recently received positive analyst coverage and its CEO was awarded a significant bonus.
Allan Jonathan, Stoke Therapeutics general counsel, sells $313k in STOK stock
Allan Jonathan, General Counsel of Stoke Therapeutics (NASDAQ:STOK), sold 9,293 shares of company stock for a total of $313,038 under a pre-arranged trading plan. This sale occurred while STOK stock is trading near its 52-week high and has shown a 303% return over the past year. The company has also received multiple positive analyst updates and its CEO was awarded a significant bonus reflecting strong performance.
Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan
Stoke Therapeutics General Counsel Jonathan Allan sold 9,293 shares of the company's common stock on March 20, 2026, through open-market transactions under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices of $33.64 and $34.41. Following these sales, Allan directly retains 19,543 shares of Stoke Therapeutics common stock.
FY2030 Earnings Estimate for STOK Issued By HC Wainwright
HC Wainwright has issued a Buy rating for Stoke Therapeutics (NASDAQ:STOK) with a $50 target price and an FY2030 EPS estimate of $4.03, significantly above the consensus estimate of ($2.01) per share. Despite broad analyst optimism, recent significant insider selling by executives like the General Counsel and CFO could temper investor sentiment. Stoke Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for rare neurological disorders, with its lead program STK-001 targeting Dravet syndrome.
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Stoke Therapeutics (NASDAQ:STOK) from a "hold" to a "sell" rating. Despite this downgrade, the analyst consensus remains a "Moderate Buy" with an average target price of $41.83, and some firms have significantly raised their price targets. Insider selling by executives, totaling over $2.5 million in the last 90 days, has introduced a negative sentiment, even as the company's stock shows positive technical indicators.
Stoke Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com
Stoke Therapeutics Inc. (NASDAQ: STOK) has received an updated analyst rating from an investment bank according to a report by Investing.com. The article, authored by Vlad Schepkov, was published on March 20, 2026, and updated the same day. This update provides significant information for investors monitoring STOK's performance and market outlook.
Form 144 STOKE THERAPEUTICS INC For: 20 March
This article announces the filing of Form 144 by STOKE THERAPEUTICS INC for March 20th. It originates from Investing.com Filings and includes basic stock performance for STOK. The content also features various market data, news headlines, and an invitation to investing challenges.
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock
Canaccord Genuity Group has increased its price target for Stoke Therapeutics (NASDAQ:STOK) from $36 to $60, maintaining a "buy" rating and implying a potential 79% upside. Several other firms have also issued bullish reports, contributing to a "Moderate Buy" consensus rating among analysts with an average price target of $41.83. Despite positive analyst sentiment and recent stock performance, the company has seen notable insider selling, with corporate insiders owning 9.50% of the stock.
Jonathan Allan plans sale of 9,293 RSUs at STOK (NASDAQ: STOK)
Jonathan Allan, an affiliate of Stoke Therapeutics (NASDAQ: STOK), plans to sell 9,293 restricted stock units (RSUs) as reported in a recent Form 144 SEC filing. The filing details two prior sales by Allan on March 17 and March 18, 2026, totaling 4,267 and 4,628 shares respectively, with associated cash amounts. The securities were acquired on March 15, 2026, as Restricted Stock Units, and the aggregate market value of the planned sale is $308,434.67.
Stoke Therapeutics stock price target raised to $60 by Canaccord on higher revenue assumptions
Canaccord Genuity has raised its price target for Stoke Therapeutics Inc. (NASDAQ:STOK) to $60 from $36, maintaining a Buy rating, due to increased revenue assumptions for the company's zorevunersen drug candidate for Dravet syndrome. This adjustment reflects the drug's potential as a disease-modifying product and the FDA's comfort with seizure frequency reduction as a path to approval. Despite a delay in the Phase 3 trial readout to mid-2027, the company is well-capitalized with a cash runway into mid-2028.
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $58,790.81 in Stock
Stoke Therapeutics (NASDAQ:STOK) Director Jason Hoitt sold 1,781 shares of company stock on March 17th for $58,790.81, and an additional 1,931 shares on March 18th for $60,517.54. These transactions reduced his total holdings to 12,207 shares. The stock performed positively during mid-day trading and multiple hedge funds adjusted their positions, while analysts maintain a "Moderate Buy" rating with an average target price near $39.83.
Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $145,041.52 in Stock
Stoke Therapeutics' General Counsel, Jonathan Allan, sold 4,628 shares of STOK stock for $145,041.52 on March 18th, and an additional 4,267 shares on March 17th for $140,853.67. These sales represent a 13.83% decrease in his position, totaling approximately $285,895 in sales over two days. Despite insider selling and recent quarterly results missing expectations, the stock traded up 7.0%, with analysts maintaining "buy" ratings and an average price target of $39.83, driven by the potential of its STK-001 program for Dravet syndrome.
Stoke Therapeutics Insider Sold Shares Worth $285,901, According to a Recent SEC Filing
An insider at Stoke Therapeutics sold shares valued at $285,901, as per a recent SEC filing. The biotech company focuses on RNA-based medicines to upregulate protein expression, with lead compounds addressing Dravet syndrome and autosomal dominant optic atrophy. This transaction is part of the company's broader activities, including recent financial results, analyst rating updates, and clinical study advancements.
Allan, Jonathan, Stoke Therapeutics general counsel, sells $285k in STOK
Jonathan Allan, General Counsel of Stoke Therapeutics (NASDAQ:STOK), sold approximately $285,900 worth of company stock across several transactions on March 17 and 18, 2026. These sales, involving 8,995 shares at prices ranging from $31.2838 to $33.3754, were primarily to cover tax withholding obligations. Following these transactions, Allan directly owns 28,836 shares.
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock
Thomas Leggett, CFO of Stoke Therapeutics (NASDAQ:STOK), sold 5,378 shares of company stock for a total of $147,144 on March 17 and 18, 2026. These sales were mandated to cover tax withholding liabilities related to restricted stock units. Recent company news includes a significant bonus for the CEO, new "Buy" coverage from Guggenheim, and an "Overweight" rating from Cantor Fitzgerald, although the Phase 3 EMPEROR study timeline for zorevunersen has been delayed.
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $60,517.54 in Stock
Stoke Therapeutics (NASDAQ:STOK) insider Jason Hoitt sold 1,931 shares of the company's stock on March 18th for a total of $60,517.54, reducing his stake by 15.82%. This follows a previous sale of 1,781 shares on March 17th. The stock recently traded up 7.0%, reaching $33.19, amidst a mix of positive analyst sentiment regarding its pipeline and negative news concerning missed quarterly earnings and potential dilution from inducement stock options.
Stoke Therapeutics (NASDAQ:STOK) CFO Sells $72,489.96 in Stock
Stoke Therapeutics (NASDAQ:STOK) CFO Thomas Leggett sold shares totaling approximately $72,489.96 on March 17th and $74,651.88 on March 18th, reducing his stake by nearly 15%. This comes as STOK rallied 7.0% due to positive analyst ratings, despite the company missing quarterly earnings and revenue expectations, and the potential for future dilution from inducement stock options. The company, focused on genetic medicines for neurological disorders, maintains a "Moderate Buy" consensus rating from analysts with an average price target of $39.83.
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 4,267 Shares
Stoke Therapeutics General Counsel Jonathan Allan sold 4,267 shares of STOK stock for $140,853.67 on March 17th, and an additional 4,628 shares on March 18th for $145,041.52, reducing his stake by 11.31%. This insider selling comes amidst mixed signals, with analysts generally bullish with a "Moderate Buy" consensus and an average price target of $39.83, but the company recently missed quarterly EPS and revenue expectations. Stoke Therapeutics, a clinical-stage biopharmaceutical company, focuses on genetic medicines for rare neuromuscular and neurological disorders using its TANGO™ platform, with its lead program STK-001 targeting Dravet syndrome.
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) CFO Sells 2,382 Shares of Stock
Stoke Therapeutics' CFO, Thomas Leggett, sold 2,382 shares of STOK stock for approximately $74,652, reducing his ownership by 18.97%. This follows a previous sale of 2,196 shares. Despite this insider selling and recent quarterly results missing expectations, analysts generally maintain a "Moderate Buy" rating for Stoke Therapeutics, with optimism surrounding its pipeline drug STK-001.
Stoke Therapeutics (NASDAQ: STOK) counsel sells shares to cover tax withholding
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics (NASDAQ: STOK), sold 8,895 shares of common stock on March 17-18, 2026. These sales were mandated by the issuer to cover tax withholding liabilities arising from the vesting of restricted stock units. Following these transactions, Allan directly holds 28,836 shares of Stoke Therapeutics common stock.
Stoke Therapeutics (NASDAQ: STOK) CFO sells 4,578 shares to cover RSU tax
Stoke Therapeutics CFO Thomas Leggett sold 4,578 shares of STOK common stock on March 17-18, 2026, to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The sales were issuer-mandated and occurred at weighted-average prices in the low $30s. Following these transactions, Leggett still directly holds 10,172 shares, indicating a tax-related disposition rather than a full divestment of his equity.
Stoke Therapeutics (STOK) CMO sells 14,311 shares in planned trades
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, exercised stock options and subsequently sold 14,311 shares of common stock in pre-planned transactions between March 17-19, 2026. These sales, conducted under a Rule 10b5-1 trading plan and partly to cover tax withholdings, are described as routine liquidity events rather than new signals about the stock. Following these trades, Ticho directly holds 40,702 shares of the company's common stock.
Stoke Therapeutics (NASDAQ: STOK) officer sells 3,712 shares in tax-driven Form 4
Stoke Therapeutics Chief Patient Officer Jason Hoitt sold 3,712 shares of common stock on March 17-18, 2026. These sales were mandated to cover tax withholding obligations on vested restricted stock units, not discretionary profit-taking. The transactions took place at weighted-average prices between $30.59 and $33.855 per share, leaving Hoitt with 10,276 directly held shares.
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 7.2% - What's Next?
Stoke Therapeutics (NASDAQ:STOK) saw its stock price rise 7.2% to $33.25, with trading volume 36% below its average. Analysts currently rate STOK as a "Moderate Buy" with a consensus price target of $39.83, following several recent price target increases. Despite institutional investors increasing their holdings, company insiders have recently sold over 38,000 shares.
Stoke Therapeutics (NASDAQ: STOK) launches $150M ATM sales agreement with Cantor
Stoke Therapeutics (NASDAQ: STOK) has initiated an At-The-Market (ATM) sales agreement with Cantor Fitzgerald & Co. to offer up to $150 million of common stock. This shelf registration provides flexible near-term financing capacity, leveraging Cantor as a sales agent. The biotech company plans to use the net proceeds for general corporate purposes, including funding research, clinical and process development, and manufacturing of its product candidates, notably advancing its Phase 3 study for zorevunersen.
Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital
Chardan Capital has reiterated a "Buy" rating for Stoke Therapeutics (NASDAQ:STOK) with a $35 price target, aligning with a broader analyst consensus for a "Moderate Buy" rating and an average target of $39.83. Despite missing quarterly earnings and revenue expectations, the stock trades near $32.87. While company insiders have recently sold shares, institutional investors like Goldman Sachs have significantly increased their holdings.
Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative
Stoke Therapeutics (STOK) reported mixed FY 2025 results, showing significant quarterly revenue and EPS fluctuations, including recent losses despite a profitable trailing 12-month period. The company faces scrutiny over its ability to maintain profitability, with a high forecast growth rate contrasting with a P/E ratio more than double the industry average. A substantial DCF fair value of US$271.73 per share significantly exceeds the current share price of US$32.87, but this gap is viewed with skepticism due to recent quarterly losses and a premium P/E relative to the wider biotech industry.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. announced the granting of stock options to six new employees as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 58,650 shares with an exercise price of $33.96 per share, are part of the company's 2023 Inducement Plan. Stoke Therapeutics is a biotechnology company focused on RNA medicine, developing treatments like zorevunersen for Dravet syndrome.
Six new Stoke Therapeutics hires get 10-year stock option packages
Stoke Therapeutics (Nasdaq: STOK) announced it granted stock options to six new employees as a material inducement for their employment. The options allow purchase of an aggregate of 58,650 shares at an exercise price of $33.96 per share, vesting over four years with a 10-year term. This move is in accordance with Nasdaq Listing Rule 5635(c)(4).
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock
Stoke Therapeutics (NASDAQ:STOK) Director Arthur Levin sold 605 shares of the company's stock for $22,264, reducing his stake by 12.49%. This sale followed Stoke missing its quarterly earnings and revenue expectations, causing shares to fall by 3.2%. Despite the missed earnings, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $39.83.
Stoke Therapeutics (STOK) director adds 61,750 shares through RSU settlements
Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake by 61,750 shares on March 15, 2026, through the settlement of Restricted Stock Units (RSUs). These RSUs, part of his compensation, vested in annual installments and were exercised at a price of $0.00 per share, not representing an open-market purchase. Following these transactions, Dr. Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.
Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares
Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, exercised 10,000 restricted stock units (RSUs) into 10,000 shares of common stock. This derivative transaction, distinct from an open-market purchase, increased his direct ownership to 13,988 common shares, with an additional 30,000 RSUs remaining. The RSUs vest in four equal annual installments starting March 15, 2026, contingent on continued service.
Stoke Therapeutics (NASDAQ: STOK) counsel exercises 25,475 RSUs into shares
Stoke Therapeutics General Counsel, Jonathan Allan, exercised 25,475 restricted stock units (RSUs) into common shares on March 15, 2026, at an exercise price of $0.00 per unit. These transactions increased his direct common stock holdings to 37,731 shares. The RSUs vest in annual installments with varying start dates contingent on his continued service to the company.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. announced that it granted stock options for 58,650 shares of common stock to six new employees on March 16, 2026. These grants, made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment, have an exercise price of $33.96 per share. The options will vest over four years, subject to continued employment, and are part of the company's efforts to advance its RNA medicine pipeline, including zorevunersen for Dravet syndrome.
Director at Stoke Therapeutics (STOK) sells 605 shares in plan trade
Arthur A. Levin, a director at Stoke Therapeutics (STOK), sold 605 shares of common stock at $36.80 per share on March 13, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. After this transaction, Levin directly holds 4,237 shares and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust. The SEC Form 4 filing details the specifics of this insider trading activity.
